Who owns Alvotech (ALVO)? Elite investor 13F holders
3 tracked elite investors reported holding Alvotech as of 2026-06-30, including Rubric Capital, Oaktree Capital Management, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | ALVOTECH SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 57848473.00 USD | 15677093.000000 | Shares | buy | Original filing |
| Oaktree Capital Management | ALVOTECH SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1073333.00 USD | 4666667.000000 | Shares | reduce | Original filing |
| Oaktree Capital Management | ALVOTECH SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 361553.00 USD | 97982.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | ALVOTECH SA | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Tudor Investment | ALVOTECH SA | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 164076.00 USD | 44465.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.